$CGEN

COMPUGEN LTD

Compugen is a clinical-stage therapeutic discovery and development company headquartered in Holon, Israel. It uses Unigen, an AI/ML-powered computational discovery platform, alongside immuno-oncology research and drug development capabilities to identify drug targets and develop cancer immunotherapies. Its pipeline includes clinical-stage programs COM701, COM902, rilvegostomig and GS-0321, as well as early-stage research programs. Compugen sponsors and conducts a clinical trial of COM701 for ovarian cancer and a Phase 1 trial of GS-0321 for advanced solid tumors. AstraZeneca develops rilvegostomig under an exclusive license, and GS-0321 is licensed to Gilead. Compugen’s business model includes selectively licensing targets and drug candidates and entering revenue-sharing collaborations with pharmaceutical and biotechnology partners. Potential payments include upfront fees, research funding, milestones, license fees and royalties. It also seeks partnerships using its discovery capabilities for research and drug development.

1
1
0

No SEC Form 4 filings for $CGEN in the last 30 days.

See all $CGEN insider activity →
Med

Compugen Ltd (CGEN) Q3 2026 Earnings Call Highlights: Revenue Doubles as Gilead

Compugen Ltd (CGEN) reported Q3 2026 revenue of $3.8M, doubling from the prior year. CEO Dr. Eran Ophir discussed milestones with AstraZeneca and Gilead, including potential payments and clinical trial updates. The company has $117.5M in cash and expects funding into 2029. Clinical trials for COM701 and GS-0321 are progressing, with data expected in 2027.

Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

CGEN sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning CGEN (COMPUGEN LTD). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.

Recent CGEN coverage spans earnings and financial news.

What's driving CGEN

AlphAI scores every news story that mentions CGEN with an AI model for sentiment and relevance, and aggregates insider trades from COMPUGEN LTD's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $CGEN

Score

Compugen stock maintained at Buy by H.C. Wainwright, $4 target

H.C. Wainwright maintained a Buy rating and $4.00 target on Compugen (CGEN) after Q3 results. The stock trades at $2.09, up 9% in a week and 37% YTD. Compugen completed enrollment for its MAIA-ovarian study, with results expected by Q1 2027. Q3 revenue was $3.8M, up from $1.9M YoY but below estimates. The company expects sufficient cash to support operations through 2029.

What Compugen (CGEN) Said on Its Q3 Earnings Call

Compugen (CGEN) reported Q3 revenue of $3.8M, up from $1.9M YoY. The company discussed milestones for its partnered programs with AstraZeneca and Gilead, including potential payments and royalties. Compugen also introduced UnigenX, an expansion of its AI-powered discovery engine. The net loss narrowed to $5.8M, or $0.06 per share, with $117.5M in cash equivalents.

Stifel reiterates Compugen stock rating on ovarian trial update

Stifel reiterated a Buy rating and $4.00 price target on Compugen (CGEN) after its investor event, citing a 73% upside potential. The event focused on the MAIA-ovarian trial and expanded UnigenX platform. Compugen reported Q2 revenue of $2.6M, a net loss of $7.0M, and a strong cash position. H.C. Wainwright also maintained a Buy rating with a $4.00 target.

Top Biotech Gainers: DERM Advances On Emrosi Growth, IOVA Revenue Climbs 66%, CAI Raises Guidance

Journey Medical (DERM) rose 13% on strong Q2 results, with revenue up 23% to $18.5M. Iovance (IOVA) gained 11% on 66% revenue growth to $99.3M. Caris (CAI) advanced 8% after raising 2026 revenue guidance to $1.03B-$1.04B. Prelude (PRLD) up 8% on narrower Q2 loss. Compugen (CGEN) gained 7% on COM701 trial progress. Conexeu (CNXU) rose 4% on regenerative aesthetics market opportunity.

Compugen Ltd Q2 Loss Drops

Compugen Ltd (CGEN) reported a Q2 GAAP net loss of $7.01 million, or $0.07 per share, improving from a $7.34 million loss, or $0.08 per share, a year earlier. Revenue rose 106.3% to $2.60 million from $1.26 million, according to the company.

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

CGEN Q2'26 Earnings: EPS estimate is (0.08) USD

Compugen Ltd. (CGEN) is scheduled to report Q2’26 results on Aug. 3 before market open, with release at 7:00 AM ET. The consensus estimates cited for Q2’26 are revenue of $1.28 million and EPS of -$0.08. The article references the company’s financials page for details.

Compugen management takes virtual Needham healthcare stage April 13

Compugen (NASDAQ: CGEN) will present at the 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, from 8:45–9:25 AM ET. A live webcast and replay will be available on the company’s investor relations website. This follows several positive corporate updates, including strong 2025 financial results, an extended cash runway, and a royalty monetization deal with AstraZeneca.

Related tickers